Changing sensory input alters how cells behave in some areas of the brain
We are studying how this affects the perception of body parts and the control of movement in humans.
RELATED PROJECTS
Causes of sleep apnoea in people with and without multiple sclerosis (MS)
This project, sponsored by MS research Australia, focuses on sleep apnoea in people with multiple sclerosis (MS). Our recent study, amongst other studies, suggests that sleep apnoea rates are higher in people with MS. However little is known about the causes of sleep apnoea in people with MS and how they might be different from people without MS. This project involves a sleep study including physiological measurements to identify differences in the causes of sleep apnoea between people with and without MS.
The Effects of "Z Drugs" in People With Obstructive Sleep Apnoea
Obstructive sleep apnoea (OSA) is a common disorder characterised by repetitive narrowing and collapse of the upper airway during sleep. It is associated with daytime sleepiness, neurocognitive impairment, and a variety of adverse cardiovascular consequences. The first line treatment for OSA is continuous positive airway pressure (CPAP) therapy. If tolerated, CPAP is highly effective in reducing sleep disordered breathing events. However, up to 50% of OSA patients are unable to tolerate CPAP therapy leaving many OSA patients without treatment.
Previous studies indicate that in selected obstructive sleep apnea participants a standard dose of a z-drug can shift the threshold for awakening during sleep (arousal) whilst maintaining the upper airway muscle activity required to keep the airway open. This study aims to investigate the effects of different doses of sleeping pills (Z-drugs) on how easily people wake up when the airway narrows during sleep, the activity of a major muscle located under the tongue (genioglossus) and obstructive sleep apnoea (OSA) severity and symptoms.
Effects of Noradrenergic and Antimuscarinic agents on Sleep Apnoea Severity
Approximately 1/3 of all obstructive sleep apnoea (OSA) patients have poor upper airway muscle activity during sleep which contributes to the repetitive narrowing or closure of the airway during sleep. This leads to abrupt arousals and disruption of sleep throughout the night which can lead to various health problems including diabetes, cardiovascular diseases, obesity, high blood pressure, impaired cognitive function, decreased quality of life and patients are more likely to be involved in motor vehicular accidents.
Recent studies have found that combination of these noradrenergic and antimuscarinic agents help to improve upper airway muscle activity during sleep. Therefore, this clinical study will focus on determining the effects of these agents on the severity of sleep apnoea in OSA patients in hopes to improve treatment outcomes for OSA patients in the future. The study also aims to determine the effects of these combination of agents on cognitive alertness and other sleep parameters which are impaired in patients with OSA.